You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK gene rearrangements

Showing 1 - 25 of 6,355
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Either EML4-ALK Gene Rearrangements or T790M EGFR Mutation in

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
    • Hollywood, Florida
    • +1 more
    Sep 29, 2021

    Lung Cancer, EGFR Gene Mutation, EGFR Trial in Charlottesville (Sensus Smartwatch Application, RX Cap, Fitbit Sense)

    Recruiting
    • Lung Cancer
    • +3 more
    • Sensus Smartwatch Application
    • +3 more
    • Charlottesville, Virginia
      University of Virginia
    Aug 26, 2022

    Lung Cancer, NSCLC, Brain Metastases Trial (Alectinib, Stereotactic Radiosurgery)

    Not yet recruiting
    • Lung Cancer
    • +2 more
    • (no location specified)
    Aug 4, 2023

    Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement Trial (TAS-120)

    Not yet recruiting
    • Advanced Cholangiocarcinoma
    • +2 more
    • (no location specified)
    Feb 3, 2023

    Radiotherapy Side Effect, NSCLC, ALK Gene Mutation Trial in Stockholm (SBRT/SRS/radiation therapy)

    Not yet recruiting
    • Radiotherapy Side Effect
    • +2 more
    • SBRT/SRS/radiation therapy
    • Stockholm, Sweden
      Karolinska University Hospital
    Feb 16, 2023

    Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer Trial in France (Blood and tumor samples)

    Recruiting
    • Soft Tissue Sarcoma
    • +2 more
    • Blood and tumor samples
    • Clermont-Ferrand, France
    • +9 more
    Dec 8, 2021

    Breast Cancer, Cholangiocarcinoma, Colorectal Cancer Trial in Worldwide (Entrectinib)

    Recruiting
    • Breast Cancer
    • +15 more
    • Goodyear, Arizona
    • +146 more
    Aug 24, 2022

    ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and

    Not yet recruiting
    • ALK Gene Mutation
    • +2 more
    • Pembrolizumab Combined With Bevacizumab and Chemotherapy
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Jul 14, 2022

    Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

    Withdrawn
    • Advanced Malignant Neoplasm
    • +10 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Feb 15, 2022

    NSCLC Stage IIIB, ALK Gene Mutation Trial in Mexico City (Alectinib Oral Product)

    Recruiting
    • Non-small Cell Lung Cancer Stage IIIB
    • ALK Gene Mutation
    • Alectinib Oral Product
    • Mexico City, Mexico
      Thoracic Oncology Unit and Personalized Medicine Laboratory, Ins
    Jan 26, 2023

    NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)

    Available
    • Non-Small Cell Lung Cancer
    • ALK Gene Rearrangement Positive
    • Stanford, California
    • +3 more
    Oct 18, 2022

    MRD Detection by NGS in Pediatric B-ALL

    Completed
    • Acute Lymphoblastic Leukemia, Pediatric, Next Generation Sequencing
    • MRD
    • Hangzhou, Zhejiang, China
      The Children's Hospital of Zhejiang University School of Medicin
    Jul 25, 2023

    Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Los Angeles (Autologous

    Recruiting
    • Lung Non-Small Cell Carcinoma
    • +3 more
    • Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
    • Pembrolizumab
    • Los Angeles, California
      UCLA / Jonsson Comprehensive Cancer Center
    Jul 21, 2022

    Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

    Active, not recruiting
    • Non Small Cell Lung Cancer
    • +5 more
    • Orange, California
    • +13 more
    Nov 7, 2022

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

    Recruiting
    • Non Small Cell Lung Cancer
      • Changsha, Hunan, China
        Yongchang Zhang
      Mar 9, 2022

      Anaplastic Lymphoma Kinase Gene Translocation, NSCLC Trial in Boston

      Recruiting
      • Anaplastic Lymphoma Kinase Gene Translocation
      • Non-Small Cell Lung Cancer
        • Boston, Massachusetts
          Massachusetts General Hospital Cancer Center
        Jan 14, 2022

        Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI

        Recruiting
        • Non-Small Cell Carcinoma of Lung, TNM Stage 4
        • +5 more
          • Aurora, Colorado
            University of Colorado, Cancer Center
          Nov 3, 2021

          Tumors, Colorectal Tumors, Melanoma Trial in United States (Alectinib)

          Terminated
          • Neoplasms
          • +27 more
          • Culver City, California
          • +28 more
          Jul 25, 2022

          Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements Trial in Worldwide (TAS-120, Cisplatin/Gemcitabine)

          Active, not recruiting
          • Advanced Cholangiocarcinoma
          • FGFR2 Gene Rearrangements
          • Albuquerque, New Mexico
          • +100 more
          Feb 1, 2023

          Non Small Cell Lung Cancer, ALK Gene Mutation Trial in France (Brigatinib 180 MG, Carboplatin, Pemetrexed)

          Recruiting
          • Non Small Cell Lung Cancer
          • ALK Gene Mutation
          • Brigatinib 180 MG
          • +2 more
          • Angers, France
          • +31 more
          Aug 9, 2022

          Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

          Not yet recruiting
          • Recurrent ALK Positive Large B-Cell Lymphoma
          • +28 more
          • Biospecimen Collection
          • +5 more
          • Rochester, Minnesota
            Mayo Clinic in Rochester
          Aug 17, 2022

          Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative Trial in

          Completed
          • Activating ALK Gene Mutation Negative
          • +7 more
          • Counseling
          • +2 more
          • Philadelphia, Pennsylvania
            Sidney Kimmel Cancer Center at Thomas Jefferson University
          Sep 7, 2022

          Frequency, Clinical Phenotype and Genetic Analysis of Heritable

          Not yet recruiting
          • Renal Tumor Histology
          • +13 more
          • Gene test
          • Shanghai, Shanghai, China
            Ethics Committee of Shanghai Renji Hospital
          Sep 6, 2022

          Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

          Recruiting
          • Nsclc
          • +5 more
          • Hong Kong, Hong Kong
            Queen Mary Hospital
          Nov 25, 2021